^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Published date:
05/17/2023
Excerpt:
For patients with prior CDK4/6 inhibitor treatment and a detectable ESR1 mutation, options include elacestrant, or other ET either alone or in combination with targeted agents such as alpelisib (for PIK3CA-mutated tumors) or everolimus.
DOI:
10.1200/JCO.23.00638